Views
4 years ago

2 - E Forte, S Baratta - Febrero 2004

  • Text
  • Estudio
  • Enfermedad
  • Coronarios
  • Placa
  • Eventos
  • Tratamiento
  • Coronary
  • Colesterol
  • Estatinas
  • Pacientes
Estatinas: de la prevención primaria a los síndromes coronarios agudos, ¿un efecto más allá de la reducción del colesterol?

Estatinas: de la

Estatinas: de la prevención primaria a los sindromes coronarios agudos, ¿un efecto más alla de la reducción del colesterol? Referencias bibliográficas 1) American Heart Asociation: Heart and Stroke Facts:1996 Statistical supplement; Dallas AHA 1996:1-26. 2) Walentin l, Lagerqvist V, Usted S y col. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II Trial. Lancet 2000; 356: 9-16. 3) Muller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med. Scand Suppl 1938;89:75-84 (abs). 4) Castelli W., Garrison R., Wilson P., et al: Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels. The Framingham Study. JAMA 1986; 256: 2835-38. 5) Stamler J., Wentworth D., Neaton J. Is relation between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-28. 6) Downs JR, Clearfield M, Weis S, y col. Primary Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-1622. 7) Sheperd J, Cobbe SM, Ford I, y col. Prevention of Coronary Heart Disease with Pravastatin in men with hipercolesterolemia. N Engl J Med. 1995;333:1301-307. 8) The Antihypertensive and lipid-lowering treatment to prevent heart attack (ALLHAT-LLT). JAMA 2002;288:2998-3007. 9) Anglo-scandinavian cardiac outcomes trial - Lipid lowering arm" (ASCOT-LLA).Lancet 2003;361: 1149-1158. 10) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-89. 11) Prevention of cardiovascular events and death with pravastatin in patiens with coronary heart disease and broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic diasease (LIPID) study group. N Eng J Med. 1998;339:1349-57. 12) Ridker P, Rifai N, Pfeffer MA, Sacks F, Moye L, Goldman G, y col. Inflamation, ravastatin, and the risk of Coronary Events After Miocardial Infarction in Patiens With Average Cholesterol Levels. The cholesterol and recurrent events (CARE) investigators.Circulation 1998;98:839-44. 13) Prospective study of pravastatin in the elderly at risk (PROSPER). Lancet 2002; 360: 1623-1630 14) Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin suplementation in a wide range of patients at increaset risk of coronary heart disease deaht. Eur Heart J.1999;20:725-741. 15) The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenus vein coronary-artery bypass grafts. NEJM.1997;336:153-62. 16) Blankenhorn D., Azen SP., Kramsch D. Y col. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS) Ann Int Med. 1993; 119:969-76. 17) Waters D., Higginson L., Gladstone P. y col. Effects of Monotherapy With an HMG-CoA Reductase Inhibitor on the Progression of Coronary Atherosclerosis as Assessed by serial Quantitative Arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994; 89:959-68. 18) Effect of Simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994; 344:633-38. 19) Jukema W, Bruschke A y col. Effects of lipid lowering by pravastatin on progresión and regression of coronary artery disease in symtomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 1995; 91:2528-2540. 20) Ahmed W, Bittl J, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am. J. Cardiol 1993; 72:544. 21) Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372. 22) Libby P, Ridker P, Masseri A. Inflammation and atherosclerosis.Circulation. 2002;105:1135-1143. 23) Liuzzo G, Biasucci LM, Gallimore JR, y col. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Eng J Med. 1994;331: 417-424. 24) Rubins HB, Robins SJ, Collins D, y col. Distribution of lipids in 8.500 men with coronary artery disease. Am J Cardiol. 1995; 75: 1196-1201. 25) Iso H, Jacobs DR, Wentworth D, y col. ,for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350.977 men screened for the multiple risk factor intervention trial. N Eng J Med. 1989;320:904-910. 26) Glenn N, Levine, Keaney J, Vita J, y col. Colesterol reduction in cardiovascular disease.N Engl J Med 1995; 332: 512-521 27) Vanhoutte PM y Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80: 1. 28) Vita JA, Treasure CB, Yeung AC y col. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85:1390-1397. 29) Bogaty P, Hackett D, Davis G y col. Vasorreactivity of the culprit lesion in unstable angina. Circulation 1994;90:5-11. 30) Liao JK, Shin WS, Lee WY y col. Oxidized Low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324. 31) Aviram M, Rosemblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998, 138:271-280. 32) Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG- CoA reductase inhibitors. Circulation 1998; 97: 1129-1135. 33) Albert MA, Staggers J, Chew P y col. The pravastatin inflammation CRP evaluation (PRINCE) Am Heart J 2001;141:881-3. 34) Lacoste L, Lam JYT, Hung J, Letchacosky G, Solimos CB, Waters D. Hyperlipemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7. 35) Egashira K, Hirooka Y, Kai H, y col. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patiens with hypercholesterolemia. Circulation 1994; 89: 2519-2524. 36) TreasureCB, Klein JL, Weintraub WS, y col. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients wiht coronary artery disease. N Engl. J. Med. 1995; 332:481-487. 37) Anderson TJ, Meredith IT, Yeung AC, y col. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 1995; 332: 488-493. 38) Dupuis J, Tardif J, Cernacek P, Teroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE Trial.Circulation 1999;99:3227-3233. 39) Hoffman R, Brock GB, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation. Atherosclerosis 1992, 93: 105-113. 40) Ferro D, Parroto S, Basili S, Allesandri C, Violi F. Sinvastatin inhibits the monocyte expression of proinflamatory cytokines in patients with hypercolesterolemia. J Am Coll Cardiol 2000, 36: 427-431. 41) O Driscoll G, Green D, Taylor RR. Sinvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131. 42) Williams JK, Sukhova GK, Herrinton DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31: 684-691. 43) Indolfi C, y col. Effects of HMG-CoA reductase inhibitor sinvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000; 35: 214-221.(abstract) 44) Bellosta S, Via D, Canavessi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998, 18: 1671-1678. 45) Kureishi Y, et al. The HMG-CoA reductase inhibitor sinvastatin activates the protein kinase akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6:1004-1010.(abstract) 46) Davi G, Averna M, Catalano I, y col. Increased thromboxane biosynthesis in type Iia hypercholesterolemia. Circulation 1992;85:1792-8. 47) Osamah H, Mira R, Sorina S. Reduced plaquet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997;44:77-83. 48) Lacoste L, Lamb YJ, Comparative effect of pravastatin and sinvastatin on platelet-thrombus formation in hipercholesterolemic coronary patients. J Am Coll Cardiol 1996;27 (Suppl A):413A. 49) Marz W, Winkelman R. HMG-CoA Reductase Inhibition in the Treatment of Atherosclesosis: Effects Beyond Lipid Lowering. J Kardiol 2002;9:284-292. 50) Buchwald H., Varco R., Matts J, y col. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hipercholesterolemia. Report of the Program on the Surgical Control of the Hiperlipidemias (POSCH) N Engl J Med 1990; 323:946-55. 51) Pitt B, Watwers D, Vigil Brown W, y col.Agressive lipid lowering therapy compared with angioplasty in stable coronary disease. N Eng J Med 1999;341:70-6. 52) Ridker P, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999;100:230-235. 53) Plenge J, Hernandez T, Weil K, Poirier P, Grunwald G, Marcovina S, and Eckel S. Simvastatin Lowers C- Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction. Circulation 2002 106: 1447 - 1452. 54) Ridker P, Rifai N, Clearfield M, Downs J, Weis SE, Miles S, y col. Measurement of c-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 26: 1959-1965. 55) Horne B, Muhlestein J, Carlquist J, Bair T, Madsen T, Hart N, y col: Statin Therapy, Lipid Levels, C-Reactive Protein and Survival of Patients Whit Angiographically Severe Coronary Artery Disease. J Am Coll Cardiol. 2000; 36: 1774-80. 56) Califf RM, Abdelmeguid AE, Kuntz RE y col. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251. 57) Walter DH, Fichtlscherer S, Britten M, Rosin P, Auch-Schwelk W, Schachinger V y col. Statin Therapy, Inflammation and Recurrent Events in Patients Following Coronary Stent Implantation. J Am Coll Cardiol 2001; 38: 2006-2012. 58) Dangas G, Badimon J, Smith A, Unger A, Levine D, Shao J, y col. Pravastatin Therapy in Hyperlipidemia: Effect on Thrombus Formation and the Systemic Hemostatic Profile. J Am Coll Cardiol 1999; 33: 1294-304. 59) Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathgenesis of coronary disease and the acute coronary syndromes. N Eng J Med 1992;326:242. 60) Sachs FM, Gibson CM, Rosner B, Pasternak RC, Stone PH, and the Hardvard Atherosclerosis reversibility Project Research Group. The influence of pretreatment low density lipoprotein cholesterol concentrationson the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiografics trials. Am J Cardiol 1995;76(suppl 9):78C-75C. 61) Vaughan C, Gotto A, Basson C. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10. 62) Arronow HD, Houghtaling PL, Topol EJ y col. Stunning reduction in death and myocardial infartion observed with early lipid lowering therapy after acute coronary syndromes.J Am Coll Cardiol 2001;37(suppl A):334A. 63) Canon CP, Mc Cabe CH, Bentley J, y col. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observación from OPUS-TIMI 16. J Am Coll Cardiol 2001;37 (suppl A):334A. 64) Hamm CW, Heeschen C, Bohen M, y col.Role of statins in patients with acute coronary syndromes. Circulation 2000;102:435. 65) Arntz H, Agrawal R, Wunderlich W. Beneficial effects of pravastatin (colestyramine-niacin) initiated inmediately after a coronary event. Am J Cardiol 2000;86:1293-1298. 66) Schwartz GG, Olson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, y col. Effects of Atrovastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. JAMA 2001; 285: 1711-1718. 67) Stenestrand U, Wallentin L, for the Swedish Registter Of Cardiac Intensive Care (RIKS-HIA). Early statin treatment folowing acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436. 68) Newby K, Kristinsson A, Bhapkar M. Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes.JAMA 2002;287:3087-3095 69) Liem A, van Boven AJ, Withagen AP, y col. Fluvastatin in acute myocardial infarction: effects on early and late ischemia and events: the FLORIDA trial (abstract).Circulation 2000;102:2672-d 70) Fonarow G, Gawlinski A, Moughrabi S. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program ( CHAMP ). Am J Cardiol 2001; 87:819-822. 71) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97. 72) ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction-2002: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 2002;106:1893. farmacologíaCardiovascular | febrero 2004 | 21

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015